Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS' broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.

"Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics," said Sam Raha, President and CEO, Myriad Genetics. "We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs."

SOPHiA GENETICS and Myriad will initially focus on the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™. Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with SOPHiA DDM™ is an innovative liquid biopsy test that detects actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA). By developing the application into a CDx, more patients can gain access to the benefits of this high-quality tumor profiling test, advancing personalized healthcare at scale.

Myriad will pursue regulatory submissions in the U.S., and SOPHiA GENETICS will manage regulatory submissions outside of the U.S. Both companies will collaborate across development activities. This innovative, hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally.

"This collaboration represents a pivotal moment for the industry," said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. "By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets."

SOPHiA GENETICS and Myriad will participate in a panel discussion at the World CB and CDx Summit in Boston and provide additional details on the collaboration.

About SOPHiA GENETICS  

SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad Genetics Safe Harbor Statement 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the company's expectation that the collaboration with SOPHiA GENETICS to support the development and commercialization of comprehensive CDx solutions for the company's BioPharma partners, add an important product offering to its menu and support the growth of its CDx programs, that by developing the application into a CDx, more patients will gain access to the benefits of this high-quality tumor profiling test, advancing personalized healthcare at scale, and that this innovative, hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/myriad-genetics-and-sophia-genetics-to-develop-an-innovative-companion-diagnostic-offering-in-liquid-biopsy-302563484.html

SOURCE SOPHiA GENETICS